Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

208

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

February 28, 2002

Conditions

HIV Infections

Interventions

DRUG

Tipranavir low dose

DRUG

Tipranavir medium dose

DRUG

Tipranavir high dose

DRUG

Ritonavir low dose

DRUG

Ritonavir high dose